Lebrikizumab (TNX-650)

Indications

Asthma (see Asthma)

  • Randomized, Double-Blinded, Placebo-Controlled Trial of Lebrikizumab in Adult Asthmatics Who Were Uncontrolled Despite Inhaled Corticosteroid Therapy (NEJM, 1011) [MEDLINE]: FEV1 studied from baseline-week 12
    • Lebrizumab Improved FEV1: lebrikizumab resulted in a larger increase in FEV1 in patients with high pre-treatment periostin levels (8.2% increase in FEV1) vs patients with low with pre-treatment periostin levels (1.6% increase in FEV1) -> therefore, high levels of IL-13 activity predicted lebrikizumab efficacy
    • Lebrikizumab Decreased the Fraction of Exhaled Nitric Oxide (FeNO) Indirectly

Pharmacology

  • IgG4 humanized monoclonal antibody that binds to IL-13: inhibits IL-13 function
    • IL-13 induces bronchial epithelial cells to secrete periostin (a matricellular protein that may induce airway remodeling in asthma)

Metabolism

  • xxx

Administration

  • xxx

Dose Adjustment

  • Hepatic: xxx
  • Renal: xxx

Adverse Effects

Rheumatologic Adverse Effects

  • Musculoskeletal Adverse Effects: occurred in 13.2% of patients (vs 5.4% on controls) [MEDLINE]

Other Adverse Effects

  • xxx
  • xxx
  • xxx
  • xxx

References

  • Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365:1088-1098 [MEDLINE]
  • Role of periostin, FENO, IL-13, lebrikzumab, other IL-13 antagonist and dual IL-4/IL-13 antagonist in asthma. Expert Opin Biol Ther. 2014 Feb;14(2):165-81. doi: 10.1517/14712598.2014.859673. Epub 2013 Nov 28 [MEDLINE]